UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

NF-κB: An essential transcription factor in psoriasis

Journal of dermatological science, 2013-02, Vol.69 (2), p.89-94

2013

Volltextzugriff (PDF)

Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials

British journal of dermatology (1951), 2015-10, Vol.173 (4), p.949-961

2015

Volltextzugriff (PDF)

Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE)

British journal of dermatology (1951), 2015-02, Vol.172 (2), p.484-493

2015

Volltextzugriff (PDF)

Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial

British journal of dermatology (1951), 2015-10, Vol.173 (4), p.930-939

2015

Volltextzugriff (PDF)

Safety results from a pooled analysis of randomized, controlled phase II and III clinical trials and interim data from an open-label extension trial of the interleukin-12/23 monoclonal antibody, briakinumab, in moderate to severe psoriasis

Journal of the European Academy of Dermatology and Venereology, 2013-10, Vol.27 (10), p.1252-1261

2013

Volltextzugriff (PDF)

Efalizumab: results of a 3-year continuous dosing study for the long-term control of psoriasis

British journal of dermatology (1951), 2008-05, Vol.158 (5), p.1107-1116

2008

Volltextzugriff (PDF)

Effects of etanercept therapy on fatigue and symptoms of depression in subjects treated for moderate to severe plaque psoriasis for up to 96 weeks

British journal of dermatology (1951), 2007-12, Vol.157 (6), p.1275-1277

2007

Volltextzugriff (PDF)

O282 EFFICACY AND SAFETY OF ADALIMUMAB TREATMENT IN WOMEN WITH MODERATE TO SEVERE HIDRADENITIS SUPPURATIVA: ANALYSIS FROM THE PLACEBO-CONTROLLED PORTION OF A PHASE II, RANDOMIZED, DOUBLE-BLIND STUDY

International journal of gynecology and obstetrics, 2012-10, Vol.119 (S3), p.S360-S360

2012

Volltextzugriff (PDF)

Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2)

British journal of dermatology (1951), 2015-12, Vol.173 (6), p.1387-1399

2015

Volltextzugriff (PDF)

A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis

British journal of dermatology (1951), 2016-08, Vol.175 (2), p.273-286

2016

Volltextzugriff (PDF)

EE162 A Claims Analysis to Characterize the Economic Burden of Generalized Pustular Psoriasis Among Patients in the United States

Value in health, 2024-06, Vol.27 (6), p.S87-S87

2024

Volltextzugriff (PDF)

CO13 A Claims Analysis To Characterize All-Cause Mortality in Patients With Generalized Pustular Psoriasis in the United States

Value in health, 2024-06, Vol.27 (6), p.S18-S18

2024

Volltextzugriff (PDF)

257 Understanding health disparities among patients with psoriasis: Results from National Psoriasis Foundation annual surveys 2019 – 2021

Journal of investigative dermatology, 2022-08, Vol.142 (8), p.S43

2022

Volltextzugriff (PDF)

Open‐label, investigator‐initiated, single‐site exploratory trial evaluating secukinumab, an anti‐interleukin‐17A monoclonal antibody, for patients with moderate‐to‐severe hidradenitis suppurativa

British journal of dermatology (1951), 2019-09, Vol.181 (3), p.609-611

2019

Volltextzugriff (PDF)

A core domain set for hidradenitis suppurativa trial outcomes: an international Delphi process

British journal of dermatology (1951), 2018-09, Vol.179 (3), p.642-650

2018

Volltextzugriff (PDF)

P50 Increasingly Stringent Clinical Responses and the Association with Improvements in Pain, HRQoL, and Work Productivity in Patients with Hidradenitis Suppurativa: 16-Week Results from Phase 3 Studies BE HEARD I&II

Value in health, 2024-06, Vol.27 (6), p.S12-S12

2024

Volltextzugriff (PDF)

Impact of previous biologic use on the efficacy and safety of brodalumab and ustekinumab in patients with moderate‐to‐severe plaque psoriasis: integrated analysis of the randomized controlled trials AMAGINE‐2 and AMAGINE‐3

British journal of dermatology (1951), 2018-08, Vol.179 (2), p.320-328

2018

Volltextzugriff (PDF)

MSR52 Defining Severity Category Thresholds to Guide Psoriasis Symptoms and Impacts Measure Score Interpretation Using Pooled Data from Three Phase 3 Trials in Plaque Psoriasis

Value in health, 2023-12, Vol.26 (12), p.S402-S403

2023

Volltextzugriff (PDF)

MSR85 Psoriasis Symptoms and Impacts Measure: Identifying Key Items Reflecting Core Symptoms of Patients with Plaque Psoriasis

Value in health, 2023-12, Vol.26 (12), p.S409

2023

Volltextzugriff (PDF)

Efficacy of secukinumab and adalimumab in patients with psoriatic arthritis and concomitant moderate‐to‐severe plaque psoriasis: results from EXCEED, a randomized, double‐blind head‐to‐head monotherapy study

British journal of dermatology (1951), 2021-12, Vol.185 (6), p.1124-1134

2021

Volltextzugriff (PDF)

Efficacy and safety of ixekizumab in a randomized, double‐blinded, placebo‐controlled phase IIIb study of patients with moderate‐to‐severe genital psoriasis

British journal of dermatology (1951), 2018-10, Vol.179 (4), p.844-852

2018

Volltextzugriff (PDF)

Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab′ certolizumab pegol: results of a phase II randomized, placebo-controlled trial with a re-treatment extension

British journal of dermatology (1951), 2012-07, Vol.167 (1), p.180-190

2012

Volltextzugriff (PDF)

Long‐term safety of certolizumab pegol in plaque psoriasis: pooled analysis over 3 years from three phase III, randomized, placebo‐controlled studies

British journal of dermatology (1951), 2021-04, Vol.184 (4), p.640-651

2021

Volltextzugriff (PDF)

Sustained efficacy of secukinumab in patients with moderate‐to‐severe palmoplantar psoriasis: 2·5‐year results from GESTURE, a randomized, double‐blind, placebo‐controlled trial

British journal of dermatology (1951), 2020-04, Vol.182 (4), p.889-899

2020

Volltextzugriff (PDF)

293 Ixekizumab demonstrates comprehensive psoriasis clearance in patients with moderate-to-severe psoriasis with scalp, nail, and/or palmoplantar involvement: Uncover-1, -2 trials through 5 years

Journal of investigative dermatology, 2022-08, Vol.142 (8), p.S50

2022

Volltextzugriff (PDF)

1 – 25 von 128

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(119)
Mit Volltextzugriff
(115)

Publikationsform

Artikel
(127)
Berichte
(1)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

NF-κB: An essential transcription factor in psoriasis

Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials

Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE)

Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial

Safety results from a pooled analysis of randomized, controlled phase II and III clinical trials and interim data from an open-label extension trial of the interleukin-12/23 monoclonal antibody, briakinumab, in moderate to severe psoriasis

Efalizumab: results of a 3-year continuous dosing study for the long-term control of psoriasis

Effects of etanercept therapy on fatigue and symptoms of depression in subjects treated for moderate to severe plaque psoriasis for up to 96 weeks

O282 EFFICACY AND SAFETY OF ADALIMUMAB TREATMENT IN WOMEN WITH MODERATE TO SEVERE HIDRADENITIS SUPPURATIVA: ANALYSIS FROM THE PLACEBO-CONTROLLED PORTION OF A PHASE II, RANDOMIZED, DOUBLE-BLIND STUDY

Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2)

A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis

EE162 A Claims Analysis to Characterize the Economic Burden of Generalized Pustular Psoriasis Among Patients in the United States

CO13 A Claims Analysis To Characterize All-Cause Mortality in Patients With Generalized Pustular Psoriasis in the United States

257 Understanding health disparities among patients with psoriasis: Results from National Psoriasis Foundation annual surveys 2019 – 2021

Open‐label, investigator‐initiated, single‐site exploratory trial evaluating secukinumab, an anti‐interleukin‐17A monoclonal antibody, for patients with moderate‐to‐severe hidradenitis suppurativa

A core domain set for hidradenitis suppurativa trial outcomes: an international Delphi process

P50 Increasingly Stringent Clinical Responses and the Association with Improvements in Pain, HRQoL, and Work Productivity in Patients with Hidradenitis Suppurativa: 16-Week Results from Phase 3 Studies BE HEARD I&II

Impact of previous biologic use on the efficacy and safety of brodalumab and ustekinumab in patients with moderate‐to‐severe plaque psoriasis: integrated analysis of the randomized controlled trials AMAGINE‐2 and AMAGINE‐3

MSR52 Defining Severity Category Thresholds to Guide Psoriasis Symptoms and Impacts Measure Score Interpretation Using Pooled Data from Three Phase 3 Trials in Plaque Psoriasis

MSR85 Psoriasis Symptoms and Impacts Measure: Identifying Key Items Reflecting Core Symptoms of Patients with Plaque Psoriasis

Efficacy of secukinumab and adalimumab in patients with psoriatic arthritis and concomitant moderate‐to‐severe plaque psoriasis: results from EXCEED, a randomized, double‐blind head‐to‐head monotherapy study

Efficacy and safety of ixekizumab in a randomized, double‐blinded, placebo‐controlled phase IIIb study of patients with moderate‐to‐severe genital psoriasis

Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab′ certolizumab pegol: results of a phase II randomized, placebo-controlled trial with a re-treatment extension

Long‐term safety of certolizumab pegol in plaque psoriasis: pooled analysis over 3 years from three phase III, randomized, placebo‐controlled studies

Sustained efficacy of secukinumab in patients with moderate‐to‐severe palmoplantar psoriasis: 2·5‐year results from GESTURE, a randomized, double‐blind, placebo‐controlled trial

293 Ixekizumab demonstrates comprehensive psoriasis clearance in patients with moderate-to-severe psoriasis with scalp, nail, and/or palmoplantar involvement: Uncover-1, -2 trials through 5 years

Suchergebnisse filtern